| Gene symbol | E7 | Synonyms | None | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_001526.4 (7604..7900) | dbXrefs | |
| Description | transforming protein E7 | ||||
| GTO ID | GTC2443 |
| Trial ID | NCT04534205 |
| Disease | Head and Neck Cancer |
| Altered gene | E7 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | BNT113 |
| Co-treatment | Pembrolizumab |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | An Open Label Phase II Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 (AHEAD-MERIT) |
| Year | 2021 |
| Country | Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|Czechia|France|Germany|Hungary|Italy|Mexico|Poland|Portugal|Spain|Sweden|Turkey|United Kingdom|United States |
| Company sponsor | BioNTech SE |
| Other ID(s) | BNT113-01|2020-001400-41 |
| Vector information | |||
|
|||
| Cohort1: BNT113_cemiplimab_Safety Run-In Phase | |||||
|
|||||
| Cohort2: BNT113_cemiplimab_Randomized phase | |||||
|
|||||
| Cohort3: cemiplimab | |||||
|
|||||